1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 3
FEATURED COMPANIES
- Amgen Inc.
- AstraZeneca Plc
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- MORE
Global Carotid Artery Stenosis Therapeutics Market: About this market
The carotid artery stenosis therapeutics market analysis considers sales from antithrombotics, antihyperlipidemic, and antihypertensives products. Our analysis also considers the sales of carotid artery stenosis therapeutics in Asia, Europe, North America, and ROW. In 2018, the antithrombotics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the use of antithrombotics as the first-line treatment option for carotid artery stenosis will play a significant role in the antithrombotics segment to maintain its market position. Also, our global carotid artery stenosis therapeutics market report looks at factors such as the increasing risk factors for carotid artery stenosis, increasing geriatric population, and growing awareness about carotid artery stenosis. However, the availability of substitutes, delay in diagnosis, and stringent regulations may hamper the growth of the carotid artery stenosis therapeutics industry over the forecast period.
Global Carotid Artery Stenosis Therapeutics Market: Overview
Growing awareness about carotid artery stenosis
The growing awareness about carotid artery stenosis is important for its prevention, as delay in the diagnosis of this disease can be life-threatening. Several awareness campaigns are being conducted globally for carotid artery stenosis that includes hemorrhagic strokes, ischemic strokes, and transient ischemic attacks. The demand for carotid artery stenosis therapeutics is increasing with the growing awareness about stroke management and carotid artery stenosis through multiple educational programs initiated by government organizations. For instance, May is observed as the National Stroke Awareness Month by the Division for Heart Disease and Stroke Prevention (DHDSP). Similarly, the Stroke Awareness Foundation promotes awareness among communities and families about the devastating effects of strokes and carotid artery stenosis. Such awareness programs lead to the expansion of the global carotid artery stenosis therapeutics market at a CAGR of over 4% during the forecast period.
Increasing demand for curative therapies
The lack of approved drugs, coupled with a high prevalence of carotid artery stenosis has driven the need for effective curative therapies. Also, the consumption of off-label drugs cause side-effects which is further increasing the demand for new curative therapies. Most patients are opting for alternative options such as stents, angioplasty, and carotid endarterectomy for the treatment of carotid artery stenosis. These developments are expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global carotid artery stenosis therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading carotid artery stenosis therapeutics manufacturers, that include Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi.
Also, the carotid artery stenosis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The carotid artery stenosis therapeutics market analysis considers sales from antithrombotics, antihyperlipidemic, and antihypertensives products. Our analysis also considers the sales of carotid artery stenosis therapeutics in Asia, Europe, North America, and ROW. In 2018, the antithrombotics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the use of antithrombotics as the first-line treatment option for carotid artery stenosis will play a significant role in the antithrombotics segment to maintain its market position. Also, our global carotid artery stenosis therapeutics market report looks at factors such as the increasing risk factors for carotid artery stenosis, increasing geriatric population, and growing awareness about carotid artery stenosis. However, the availability of substitutes, delay in diagnosis, and stringent regulations may hamper the growth of the carotid artery stenosis therapeutics industry over the forecast period.
Global Carotid Artery Stenosis Therapeutics Market: Overview
Growing awareness about carotid artery stenosis
The growing awareness about carotid artery stenosis is important for its prevention, as delay in the diagnosis of this disease can be life-threatening. Several awareness campaigns are being conducted globally for carotid artery stenosis that includes hemorrhagic strokes, ischemic strokes, and transient ischemic attacks. The demand for carotid artery stenosis therapeutics is increasing with the growing awareness about stroke management and carotid artery stenosis through multiple educational programs initiated by government organizations. For instance, May is observed as the National Stroke Awareness Month by the Division for Heart Disease and Stroke Prevention (DHDSP). Similarly, the Stroke Awareness Foundation promotes awareness among communities and families about the devastating effects of strokes and carotid artery stenosis. Such awareness programs lead to the expansion of the global carotid artery stenosis therapeutics market at a CAGR of over 4% during the forecast period.
Increasing demand for curative therapies
The lack of approved drugs, coupled with a high prevalence of carotid artery stenosis has driven the need for effective curative therapies. Also, the consumption of off-label drugs cause side-effects which is further increasing the demand for new curative therapies. Most patients are opting for alternative options such as stents, angioplasty, and carotid endarterectomy for the treatment of carotid artery stenosis. These developments are expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global carotid artery stenosis therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading carotid artery stenosis therapeutics manufacturers, that include Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi.
Also, the carotid artery stenosis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 3
FEATURED COMPANIES
- Amgen Inc.
- AstraZeneca Plc
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Antithrombotics - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antithrombotics - Year-over-year growth 2019-2023 (%)
Exhibit 22: Antihyperlipidemics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Antihyperlipidemics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Antihypertensives - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Antihypertensives - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Amgen Inc. - Vendor overview
Exhibit 51: Amgen Inc. - Business segments
Exhibit 52: Amgen Inc. - Organizational developments
Exhibit 53: Amgen Inc. - Geographic focus
Exhibit 54: Amgen Inc. - Key offerings
Exhibit 55: Amgen Inc. - Key customer
Exhibit 56: AstraZeneca Plc - Vendor overview
Exhibit 57: AstraZeneca Plc - Business segments
Exhibit 58: AstraZeneca Plc - Organizational developments
Exhibit 59: AstraZeneca Plc - Geographic focus
Exhibit 60: AstraZeneca Plc - Key offerings
Exhibit 61: AstraZeneca Plc - Key customers
Exhibit 62: Boehringer Ingelheim International GmbH - Vendor overview
Exhibit 63: Boehringer Ingelheim International GmbH - Business segments
Exhibit 64: Boehringer Ingelheim International GmbH - Organizational developments
Exhibit 65: Boehringer Ingelheim International GmbH - Geographic focus
Exhibit 66: Boehringer Ingelheim International GmbH - Segment focus
Exhibit 67: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 68: Boehringer Ingelheim International GmbH - Key customers
Exhibit 69: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 70: Bristol-Myers Squibb Co. - Business segments
Exhibit 71: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 72: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 73: Bristol-Myers Squibb Co. - Key offerings
Exhibit 74: Bristol-Myers Squibb Co. - Key customers
Exhibit 75: Eli Lilly and Co. - Vendor overview
Exhibit 76: Eli Lilly and Co. - Business segments
Exhibit 77: Eli Lilly and Co. - Organizational developments
Exhibit 78: Eli Lilly and Co. - Geographic focus
Exhibit 79: Eli Lilly and Co. - Segment focus
Exhibit 80: Eli Lilly and Co. - Key offerings
Exhibit 81: Eli Lilly and Co. - Key customers
Exhibit 82: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 83: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 84: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 85: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 86: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 87: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 88: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 89: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 90: Johnson & Johnson Services, Inc. - Business segments
Exhibit 91: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 92: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 93: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 94: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 95: Johnson & Johnson Services, Inc. - Key customers
Exhibit 96: Merck & Co. Inc. - Vendor overview
Exhibit 97: Merck & Co. Inc. - Business segments
Exhibit 98: Merck & Co. Inc. - Organizational developments
Exhibit 99: Merck & Co. Inc. - Geographic focus
Exhibit 100: Merck & Co. Inc. - Segment focus
Exhibit 101: Merck & Co. Inc. - Key offerings
Exhibit 102: Merck & Co. Inc. - Key customers
Exhibit 103: Pfizer Inc. - Vendor overview
Exhibit 104: Pfizer Inc. - Business segments
Exhibit 105: Pfizer Inc. - Organizational developments
Exhibit 106: Pfizer Inc. - Geographic focus
Exhibit 107: Pfizer Inc. - Segment focus
Exhibit 108: Pfizer Inc. - Key offerings
Exhibit 109: Pfizer Inc. - Key customers
Exhibit 110: Sanofi - Vendor overview
Exhibit 111: Sanofi - Business segments
Exhibit 112: Sanofi - Organizational developments
Exhibit 113: Sanofi - Geographic focus
Exhibit 114: Sanofi - Segment focus
Exhibit 115: Sanofi - Key offerings
Exhibit 116: Sanofi - Key customers
Exhibit 117: Validation techniques employed for market sizing
Exhibit 118: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by product
- Comparison by product
- Antithrombotics - Market size and forecast 2018-2023
- Antihyperlipidemics - Market size and forecast 2018-2023
- Antihypertensives - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Entry of generic drugs
- Technological advances in medical devices
- Increasing demand for curative therapies
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Amgen Inc.
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Antithrombotics - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antithrombotics - Year-over-year growth 2019-2023 (%)
Exhibit 22: Antihyperlipidemics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Antihyperlipidemics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Antihypertensives - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Antihypertensives - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Amgen Inc. - Vendor overview
Exhibit 51: Amgen Inc. - Business segments
Exhibit 52: Amgen Inc. - Organizational developments
Exhibit 53: Amgen Inc. - Geographic focus
Exhibit 54: Amgen Inc. - Key offerings
Exhibit 55: Amgen Inc. - Key customer
Exhibit 56: AstraZeneca Plc - Vendor overview
Exhibit 57: AstraZeneca Plc - Business segments
Exhibit 58: AstraZeneca Plc - Organizational developments
Exhibit 59: AstraZeneca Plc - Geographic focus
Exhibit 60: AstraZeneca Plc - Key offerings
Exhibit 61: AstraZeneca Plc - Key customers
Exhibit 62: Boehringer Ingelheim International GmbH - Vendor overview
Exhibit 63: Boehringer Ingelheim International GmbH - Business segments
Exhibit 64: Boehringer Ingelheim International GmbH - Organizational developments
Exhibit 65: Boehringer Ingelheim International GmbH - Geographic focus
Exhibit 66: Boehringer Ingelheim International GmbH - Segment focus
Exhibit 67: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 68: Boehringer Ingelheim International GmbH - Key customers
Exhibit 69: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 70: Bristol-Myers Squibb Co. - Business segments
Exhibit 71: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 72: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 73: Bristol-Myers Squibb Co. - Key offerings
Exhibit 74: Bristol-Myers Squibb Co. - Key customers
Exhibit 75: Eli Lilly and Co. - Vendor overview
Exhibit 76: Eli Lilly and Co. - Business segments
Exhibit 77: Eli Lilly and Co. - Organizational developments
Exhibit 78: Eli Lilly and Co. - Geographic focus
Exhibit 79: Eli Lilly and Co. - Segment focus
Exhibit 80: Eli Lilly and Co. - Key offerings
Exhibit 81: Eli Lilly and Co. - Key customers
Exhibit 82: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 83: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 84: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 85: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 86: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 87: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 88: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 89: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 90: Johnson & Johnson Services, Inc. - Business segments
Exhibit 91: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 92: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 93: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 94: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 95: Johnson & Johnson Services, Inc. - Key customers
Exhibit 96: Merck & Co. Inc. - Vendor overview
Exhibit 97: Merck & Co. Inc. - Business segments
Exhibit 98: Merck & Co. Inc. - Organizational developments
Exhibit 99: Merck & Co. Inc. - Geographic focus
Exhibit 100: Merck & Co. Inc. - Segment focus
Exhibit 101: Merck & Co. Inc. - Key offerings
Exhibit 102: Merck & Co. Inc. - Key customers
Exhibit 103: Pfizer Inc. - Vendor overview
Exhibit 104: Pfizer Inc. - Business segments
Exhibit 105: Pfizer Inc. - Organizational developments
Exhibit 106: Pfizer Inc. - Geographic focus
Exhibit 107: Pfizer Inc. - Segment focus
Exhibit 108: Pfizer Inc. - Key offerings
Exhibit 109: Pfizer Inc. - Key customers
Exhibit 110: Sanofi - Vendor overview
Exhibit 111: Sanofi - Business segments
Exhibit 112: Sanofi - Organizational developments
Exhibit 113: Sanofi - Geographic focus
Exhibit 114: Sanofi - Segment focus
Exhibit 115: Sanofi - Key offerings
Exhibit 116: Sanofi - Key customers
Exhibit 117: Validation techniques employed for market sizing
Exhibit 118: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 3
LOADING...
4 of 3
- Amgen Inc.
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi
Note: Product cover images may vary from those shown
